Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
5
|
| pubmed:dateCreated |
1998-2-4
|
| pubmed:abstractText |
In order to estimate the therapeutic activity and tolerability of immunochemotherapy with recombinant interferon-alpha 2b (rIFN-alpha 2b) plus dacarbazine (DTIC), a study was carried out in 61 patients with cytologically and/or histologically confirmed metastatic malignant melanoma. The treatment regimen was as follows: rIFN-alpha 2b 2 x 10(6) IU intramuscularly on days 1 to 4, and DTIC 800 mg/m2 intravenously on day 5, repeated at 3-week intervals until the progression of the disease or, in the case of a complete response, for up to 6 months. The overall response rate was 28%-12% complete response (CR) and 16% partial response (PR). The median response duration was 10.9 months (CR 11.5 months, PR 9.3 months; P > 0.05). Responses occurred in soft tissue and lung metastases only. The median times to treatment failure for responding and non-responding patients were 10.9 and 3 months, respectively (P < 0.0001), and the median survival durations were 16.5 and 5.8 months, respectively (P < 0.0001). The stratification of the patients into a low-risk group (World Health Organization performance status [WHO PS] < or = 1 and soft tissue or lung metastases) and a high-risk group (WHO PS = 2 or disease localization other than skin, lymph nodes or lung) showed a significant advantage for the first group with respect to the response rate, median time to treatment failure and survival duration. A flu-like syndrome was recorded in 72% of patients, nausea and vomiting in 34%, haematological toxicity in 26%, hepatic toxicity in 5%, and neurotoxicity in 5%. In view of the results obtained in our study and those reported in the literature, IFN plus DTIC immunochemotherapy represents a reasonable treatment option, particularly for patients with soft tissue and lung metastases.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antineoplastic Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Dacarbazine,
http://linkedlifedata.com/resource/pubmed/chemical/Interferon-alpha,
http://linkedlifedata.com/resource/pubmed/chemical/Recombinant Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/interferon alfa-2b
|
| pubmed:status |
MEDLINE
|
| pubmed:month |
Oct
|
| pubmed:issn |
0960-8931
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
7
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
420-7
|
| pubmed:dateRevised |
2011-11-17
|
| pubmed:meshHeading |
pubmed-meshheading:9429226-Adult,
pubmed-meshheading:9429226-Aged,
pubmed-meshheading:9429226-Antineoplastic Agents,
pubmed-meshheading:9429226-Combined Modality Therapy,
pubmed-meshheading:9429226-Dacarbazine,
pubmed-meshheading:9429226-Disease-Free Survival,
pubmed-meshheading:9429226-Female,
pubmed-meshheading:9429226-Humans,
pubmed-meshheading:9429226-Interferon-alpha,
pubmed-meshheading:9429226-Lung Neoplasms,
pubmed-meshheading:9429226-Lymphatic Metastasis,
pubmed-meshheading:9429226-Male,
pubmed-meshheading:9429226-Melanoma,
pubmed-meshheading:9429226-Middle Aged,
pubmed-meshheading:9429226-Neoplasm Metastasis,
pubmed-meshheading:9429226-Neoplasm Staging,
pubmed-meshheading:9429226-Recombinant Proteins,
pubmed-meshheading:9429226-Skin Neoplasms,
pubmed-meshheading:9429226-Soft Tissue Neoplasms,
pubmed-meshheading:9429226-Survival Rate,
pubmed-meshheading:9429226-Time Factors
|
| pubmed:year |
1997
|
| pubmed:articleTitle |
Immunochemotherapy with recombinant interferon-alpha 2b plus dacarbazine in the treatment of advanced malignant melanoma.
|
| pubmed:affiliation |
Institute of Oncology, Ljubljana, Slovenia.
|
| pubmed:publicationType |
Journal Article
|